Skip to main content

Table 2 Frequency distribution of patient characteristic variables for people initiating daily-dose isoniazid treatment and the proportion of people completing treatment by each characteristic. Treatment completion was categorized as 1) less than 6 months completed, 2) at least 6 months but less than 9 months completed, and 3) 9 or more months completed

From: Predictors of latent tuberculosis infection treatment completion in the US private sector: an analysis of administrative claims data

   Distribution % Achieving Each Level of Isoniazid Treatment Completion % Completing ≥6 Mo.
N % or Mean of Total < 6 Months Complete
[% or Mean]
≥6 but < 9 Months Complete
[% or Mean]
≥9 Months Complete
[% or Mean]
p-value: 3 Completion Levels ≥6 Months Complete
[% or Mean]
p-value: < 6 vs ≥6 Months Complete
Sex Female 575 53.6% 55.8% 22.1% 22.1% 0.232 44.2% 0.158
Male 497 46.4% 51.5% 25.4% 23.1%   48.5%  
Age Group 0–14 105 9.8% 43.8% 24.8% 31.4% 0.019 56.2% 0.064
15–29 291 27.1% 58.8% 23.4% 17.9%   41.2%  
30–44 321 29.9% 53.9% 25.2% 20.9%   46.1%  
45–64 355 33.1% 52.7% 22.0% 25.3%   47.3%  
Census Region Northeast 352 32.8% 54.8% 20.5% 24.7% 0.148 45.2% 0.151
Midwest 174 16.2% 52.3% 25.3% 22.4%   47.7%  
South 148 13.8% 61.5% 22.3% 16.2%   38.5%  
West 398 37.1% 53.8% 23.6% 22.6%   46.2%  
Patient Location Large central metro county 484 45.1% 50.0% 26.7% 23.4% 0.169 50.0% 0.066
Large fringe metro county 413 38.5% 57.6% 19.6% 22.8%   42.4%  
Any smaller county 175 16.3% 55.4% 24.6% 20.0%   44.6%  
% of Households Under FPL in County < 15% 596 55.6% 51.7% 22.8% 25.5% 0.035 48.3% 0.115
≥15% 476 44.4% 56.5% 24.6% 18.9%   43.5%  
Insurance Type HMO 188 17.5% 62.2% 21.3% 16.5% 0.005 37.8% 0.022
POS 742 69.2% 52.8% 25.1% 22.1%   47.2%  
PPO 142 13.2% 47.9% 19.0% 33.1%   52.1%  
INH Days Supply Received on Date of 1st Fill < 2 month supply 991 92.4% 54.5% 24.1% 21.4% 0.020 45.5% 0.126
≥2 month supply 81 7.6% 45.7% 17.3% 37.0%   54.3%  
Year INH Regimen Started 2011 Q3–4 230 21.5% 58.3% 23.0% 18.7% 0.308 41.7% 0.298
2012 Q1–4 450 42.0% 54.4% 21.8% 23.8%   45.6%  
2013 Q1–4 346 32.3% 50.3% 26.3% 23.4%   49.7%  
2014 Q1 46 4.3% 52.2% 23.9% 23.9%   47.8%  
State TB Rate   3.85 3.84 3.81 0.846 3.83 0.864
LTBI Diagnostic Test TST 441 41.1% 53.5% 22.9% 23.6% < 0.001 46.5% 0.005
IGRA 219 20.4% 45.2% 23.7% 31.1%   54.8%  
Unknown/ Other 412 38.4% 58.7% 24.3% 17.0%   41.3%  
Percent Foreign Born in County   19.96 20.24 20.97 0.403 20.60 0.516
Count of Clinical Risk Factors None 662 61.8% 58.0% 22.2% 19.8% 0.011 42.0% 0.002
1 304 28.4% 47.7% 27.0% 25.3%   52.3%  
2 or more 106 9.9% 45.3% 22.6% 32.1%   54.7%  
Diagnosis of Contact w/ TBa No diagnosis 923 86.1% 54.3% 23.8% 21.9% 0.296 45.7% 0.457
Had diagnosis 149 13.9% 51.0% 22.2% 26.9%   49.0%  
History of TB/ Late Effects No diagnosis 1027 95.8% 54.2% 23.1% 22.7% 0.426 45.8% 0.197
Had diagnosis 45 4.2% 44.4% 35.6% 20.0%   55.6%  
HIV Positive No diagnosis 1030 96.1% 54.7% 23.4% 21.9% 0.004 45.3% 0.007
Had diagnosis 42 3.9% 33.3% 28.6% 38.1%   66.7%  
Diabetes No diagnosis 999 93.2% 54.5% 23.5% 22.0% 0.085 45.6% 0.126
Had diagnosis 73 6.8% 45.2% 24.7% 30.1%   54.8%  
Tobacco No diagnosis or medication 1004 93.7% 54.2% 23.7% 22.1% 0.237 45.8% 0.366
Had diagnosis or medication 68 6.3% 48.5% 22.1% 29.4%   51.5%  
Immuno-suppressive Medication No medication 948 88.4% 55.1% 23.0% 21.9% 0.030 44.9% 0.025
Had medication 124 11.6% 44.4% 28.2% 27.4%   55.6%  
  1. aBased on an ICD-9-CM code of V01.1. Abbreviations: INH isoniazid, FPL federal poverty level, TB tuberculosis, TST tuberculin skin test, IGRA interferon-gamma release assays, LTBI latent tuberculosis infection, HMO health maintenance organization, POS point of service, PPO preferred provider organization